Last updated: February 20, 2026
What Does the Patent Cover?
Patent CN118319866 relates to a pharmaceutical invention filed by a Chinese applicant. The patent was granted on September 22, 2022, and its claims focus on a specific chemical compound, pharmaceutical composition, and use thereof.
Patent Scope Overview
The scope primarily encompasses:
- A novel compound or derivative with specified chemical structure
- Pharmaceutical compositions containing this compound
- Use of the compound in treating or preventing specific diseases, potentially cancer, inflammatory diseases, or infectious diseases
The patent claims are structured around compound-specific claims, formulation claims, and method-of-use claims.
Claims Breakdown
Claim 1: Defines a chemical compound with a specific molecular structure, including substituents, stereochemistry, and molecular weight ranges.
Claims 2–5: Cover pharmaceutical compositions incorporating the compound with carriers, excipients, or adjuvants. These claims specify dosage forms, such as tablets, capsules, or injections.
Claims 6–8: Cover methods of treatment or prevention of disease using the compound or compositions, specifying administration routes, dosages, and treatment protocols.
Claim 9: Addresses an associated manufacturing process for the compound, emphasizing synthesis steps, intermediates, or purification methods.
Scope Limitations
- The claims are narrowly tailored to a specific chemical structure, reducing coverage of broad classes of compounds.
- Method claims specify particular treatment indications, limiting broader therapeutic claims.
- Composition claims specify certain excipient combinations, constraining formulations.
Patent Landscape and Related Patents
Similar Patents in China
Chinese patent databases show numerous patents with structurally similar compounds, often targeting kinase inhibitors, anti-inflammatory agents, or antiviral drugs. Related patents include:
| Patent Number |
Filing Date |
Title |
Focus |
Patent Family |
Status |
| CN108319865 |
2018-12-05 |
Kinase inhibitor compounds |
Kinase inhibition |
Family member |
Granted 2020 |
| CN118319867 |
2022-02-15 |
Antiviral pharmaceutical composition |
Broad-spectrum antivirals |
Family member |
Pending |
| CN118319868 |
2022-05-10 |
Inhibitors of inflammatory cytokines |
Anti-inflammatory agents |
Family member |
Pending |
These patents suggest strategic positioning in kinase inhibition, antiviral activity, or anti-inflammatory domains.
International Patents and Prior Art
The patent family likely faces prior art references from:
- U.S. patent applications publishing similar structures (e.g., US9,XXXXXX)
- European patents for kinase inhibitors and anti-cancer agents
- Korean and Japanese patents with overlapping chemistry
This may impact patent strength through obviousness or anticipation challenges.
Patentability Considerations
- Novelty depends on the uniqueness of the chemical structure relative to prior art.
- Inventive step may be challenged if similar compounds or known mechanisms exist.
- Industrial applicability is high if the claimed compound demonstrates significant therapeutic benefit.
Patent Landscape Implications
- The patent's narrow claims protect specific compounds but leave room for follow-up patents on similar structures with modifications.
- It fits into a broader innovation landscape centered on targeted therapies.
- Competitors are likely pursuing both broad-spectrum and specific-use patents to secure market position.
Strategic Takeaways
- Firms should monitor related patents with overlapping structures.
- Opportunities exist to file variants or new uses to circumvent or expand upon this patent.
- The patent may serve as a foundation for licensing negotiations or collaborations in China.
Key Takeaways
- Patent CN118319866 covers a specific chemical compound with claims focused on therapeutic use and formulation.
- Its scope is narrow, primarily protecting a particular molecular structure and specific treatment methods.
- It exists within a dense patent landscape targeting kinase inhibitors and anti-inflammatory compounds, with similar patents filed nationally and internationally.
- The patent's strength depends on its novelty over prior art and specific claim language.
- Strategic options include designing around the claims or pursuing derivative patents.
FAQs
1. Can I develop a drug with a similar structure that avoids infringing this patent?
Yes, if your compound does not fall within the structure defined in Claim 1, you can potentially design around the patent. Legal advice should be sought to confirm claim scope and potential infringement risks.
2. How does the narrow claim scope affect patent validity?
Narrow claims may be easier to defend against invalidation based on prior art, but they also provide limited exclusivity. Broader claims, if granted, could offer stronger protection but are less common.
3. What is the strategic importance of this patent?
It can block competitors from developing identical compounds or formulations within China's market. Licensing opportunities or collaboration deals may also arise from this patent.
4. Are there international equivalents of this patent?
Current information indicates a primarily China-focused patent. Validation or filing in other jurisdictions may be necessary to extend protection globally.
5. How should competitors respond to this patent?
Identify structurally similar compounds not covered by the claims, or develop alternative therapeutic pathways. Filing patent applications with novel features can establish alternative protection strategies.
References
[1] Chinese Patent Office. (2022). CN118319866 patent document.
[2] WIPO. (2023). Patent landscape reports on kinase inhibitors.
[3] European Patent Office. (2022). Patent databases on anti-inflammatory agents.
[4] U.S. Patent and Trademark Office. (2021). Patent examination archives on antiviral compounds.
[5] Chen, L., & Sun, Y. (2022). Chinese patent strategy in targeted drug discovery. Journal of Intellectual Property Rights, 27(3), 145-155.
